Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex Peptide Drug Conjugate (PDC) tumor targeting platform, today announced the completion of its $25 million Series B financing. The financing included HighCape Capital and new investor Elm Street Ventures. Proceeds from the financing will be used to support the planned advancement of Cybrexa's lead candidate CBX-12 (alphalex-exatecan) into the clinic. The first patient dosing in the Phase 1 study is expected in the first half of 2021.

Cybrexa is a privately funded biotechnology company dedicated to developing an entirely new class of small molecule DNA repair inhibitors (TSDs) that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. The Company is led by an experienced team of researchers and business executives who have developed and commercialized technologies, launched products, driven sales, negotiated partnerships, and led a number of companies from start up to liquidity events.